| Size | Price | Stock | Qty |
|---|---|---|---|
| 500g |
|
||
| Other Sizes |
| Targets |
2-Bromothiazole does not have a defined pharmacological target. It is a heterocyclic compound that has been reported to induce base-pair substitution and have mutagenic activity. The compound is primarily used as a chemical reagent and building block for the synthesis of various biologically active compounds, including 2-cyanothiazole via copper-catalyzed cyanation and N-arylated azaindoles.
|
|---|---|
| ln Vitro |
2-Bromothiazole, solely for research purposes. Additionally, 5- and 7-azaindoles are N-arylated using it as an aryl halide. The product of copper-catalyzed cyanation is 2-cyanothiazole.
In vitro, 2-Bromothiazole is primarily used as a chemical reagent and synthetic intermediate. It is used to N-arylate 5- and 7-azaindoles and as a starting reagent in the synthesis of 2-cyanothiazole via copper-catalyzed cyanation. The compound is employed in the synthesis of various pharmaceutical compounds that are subsequently tested in in vitro assays. It is soluble in chloroform and dichloromethane. |
| ln Vivo |
In vivo activity data for 2-Bromothiazole itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates that are subsequently evaluated in animal models. The compound's in vivo relevance is indirect, through the biological activities of the final pharmaceutical compounds derived from it.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding studies, 2-Bromothiazole is not typically evaluated as a test compound itself. Instead, it serves as a reagent for the synthesis of test compounds. The compound's properties include a molecular weight of 164.02 g/mol, a predicted pKa of 0.84±0.10, and a density of 1.82 g/mL. The bromine atom provides a versatile handle for cross-coupling reactions.
|
| Cell Assay |
For in vitro cell-based experiments, 2-Bromothiazole is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations in appropriate cell culture medium.
|
| Animal Protocol |
In vivo animal studies using 2-Bromothiazole are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For pharmaceutical candidates derived from this building block, efficacy studies would typically be performed in mouse models of the relevant disease. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection, with appropriate pharmacokinetic and pharmacodynamic endpoints.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-Bromothiazole as a standalone compound are not characterized in the literature. The compound has a molecular weight of 164.02 g/mol, which is within the favorable range for oral bioavailability. The compound has a predicted pKa of 0.84, indicating it will be largely un-ionized at physiological pH. Empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
2-Bromothiazole is classified with GHS hazard statements H227-H315-H319-H335. Hazard codes include Xi and F. Risk statements include R36/37/38: Irritating to eyes, respiratory system and skin. Safety statements recommend S23: Do not breathe gas/fumes/vapor/spray, S24/25: Avoid contact with skin and eyes, and S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. The compound has a flash point of 146°F.
|
| Additional Infomation |
2-Bromothiazole (CAS 3034-53-5) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are in organic synthesis as a building block for heterocyclic compounds. The compound is used to N-arylate azaindoles and as a starting reagent for the synthesis of 2-cyanothiazole. It has been reported to have mutagenic activity. No clinical trials or approved indications exist for this compound. It is intended for laboratory research use only.
|
| Molecular Formula |
C3H2BRNS
|
|---|---|
| Molecular Weight |
164.02
|
| Exact Mass |
162.909
|
| CAS # |
3034-53-5
|
| PubChem CID |
76430
|
| Appearance |
Colorless to light yellow liquid（Density：1.857±0.06 g/cm3）
|
| Density |
1.9±0.1 g/cm3
|
| Boiling Point |
171.0±9.0 °C at 760 mmHg
|
| Melting Point |
171ºC
|
| Flash Point |
63.3±0.0 °C
|
| Vapour Pressure |
1.9±0.3 mmHg at 25°C
|
| Index of Refraction |
1.605
|
| LogP |
1.93
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
6
|
| Complexity |
50.1
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1=NC=CS1
|
| InChi Key |
RXNZFHIEDZEUQM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C3H2BrNS/c4-3-5-1-2-6-3/h1-2H
|
| Chemical Name |
2-bromo-1,3-thiazole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0968 mL | 30.4841 mL | 60.9682 mL | |
| 5 mM | 1.2194 mL | 6.0968 mL | 12.1936 mL | |
| 10 mM | 0.6097 mL | 3.0484 mL | 6.0968 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
